Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that p300, a protein that increases gene expression by attaching acetyl molecules to DNA, may stop myelodysplastic syndrome (MDS) from developing into acute myeloid leukemia (AML). The study was published in the journal Leukemia.
"The loss of p300 allows these defective cells to grow and become leukemic," said Sylvester Director Stephen Nimer, M.D., principal investigator of the study. "This work offers us a window into AML, which we are now going to try to exploit."
MDS affects blood stem cells, preventing them from becoming mature, healthy blood cells. Around a third of MDS patients develop leukemia. For Nimer, who has been studying MDS for three decades, teasing out new information about the function of p300 could generate new insights and possibly new therapeutics.
The p300 protein, along with its close cousin CBP, is part of a family of molecules called histone acetyltransferases (HATs). By adding acetyl groups to the histones that package DNA, they help turn on genes.
Previous studies have indicated that p300 and CBP may promote cancer under certain circumstances. However, in this study, the team found that mice without p300 rapidly developed leukemia. Surprisingly, despite its close relationship to p300 and similar structure, CBP deletion had no effect.
"When we eliminated p300, 100 percent of the mice developed leukemia," said Nimer. "It indicated that, under this specific circumstance, p300 is a tumor suppressor, offering great insight into how MDS converts to leukemia. It was quite surprising that CBP plays no role at all."
"While investigating how p300 functions in MDS cells, we found that MDS cells do not grow well in the lab," said Nimer. "However, when you eliminate p300, suddenly the cells continue to grow."
While p300 apparently plays a critical role in MDS progressing to leukemia, this function is highly contextual as the protein has no obvious effect on healthy stem cells. Nimer and his colleagues believe the molecular variations that drive MDS also make them vulnerable to p300 loss of deficiency. Now that p300 has been established as a tumor suppressor, the team will begin delineating the pathways it uses to control MDS cells. These findings could ultimately help MDS patients avoid leukemia.
"Other than chemotherapy, right now, there's no way to prevent MDS from developing into myeloid leukemia," said Nimer. "However, drugs are being developed that can promote p300 function and possibly prevent MDS patients from developing leukemia."
About Sylvester Comprehensive Cancer Center
Sylvester Comprehensive Cancer Center, part of UHealth - the University of Miami Health System and the University of Miami Miller School of Medicine, is among the nation's leading cancer centers and South Florida's only Cancer Center of Excellence. A 2015 study by Memorial Sloan Kettering Cancer Center, published in The Journal of the American Medical Association, showed that cancer patients treated at Sylvester have a 10 percent higher chance of survival than those treated at nearly any other cancer center in the nation. With the combined strength of more than 120 cancer researchers and 130 cancer specialists, Sylvester discovers, develops and delivers more targeted therapies, providing the next generation of cancer clinical care - precision cancer medicine - to each patient. Our comprehensive diagnostics, coupled with teams of scientific and clinical experts who specialize in just one type of cancer, enable us to better understand each patient's individual cancer and develop treatments that target the cells and genes driving the cancer's growth and survival, leading to better outcomes. At Sylvester, patients have access to more treatment options and more cancer clinical trials than most hospitals in the southeastern United States. To better serve current and future patients, Sylvester has a network of conveniently located outpatient treatment facilities in Miami, Kendall, Hollywood, Plantation, Deerfield Beach, Coral Springs, and Coral Gables. For more information, visit sylvester.org.
Patrick Bartosch | EurekAlert!
How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine
Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center
On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.
We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...
What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...
For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.
Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...
At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.
No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...
Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.
Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...
08.01.2018 | Event News
11.12.2017 | Event News
08.12.2017 | Event News
19.01.2018 | Materials Sciences
19.01.2018 | Health and Medicine
19.01.2018 | Physics and Astronomy